LENZ Therapeutics (NasdaqGS:LENZ) FY Conference Transcript

Summary of LENZ Therapeutics FY Conference Call Company Overview - Company: LENZ Therapeutics (NasdaqGS:LENZ) - Product: Viz, a novel presbyopia eyedrop based on aceclidine, recently approved by the FDA for commercial launch [3][4][6] Core Points and Arguments Product Approval and Launch - Viz is designed to restore near vision for a full workday, allowing users to see as they did in their 30s and 40s [4][5] - The commercial launch is underway, with a salesforce of 88 representatives actively promoting the product since July 1, 2025 [6][7] Commercial Strategy - The strategy focuses on three pillars: 1. Doctors recommending the product 2. Consumers requesting it by name 3. Ensuring seamless access for consumers [6] - Product samples will be available in October, with the aim of building confidence among doctors and consumers [7][8] Market Positioning - Viz is positioned as a cash-pay product, avoiding the complexities of insurance negotiations, which simplifies revenue generation [9][10] - The product is expected to fill a gap in the market for effective presbyopia treatments, as evidenced by the initial success of similar products like AbbVie’s Vuity [10][11] Efficacy and Competitive Advantage - Clinical trials showed that 93% of patients achieved 20/40 vision or better within 30 minutes, with 70% maintaining this vision for up to 10 hours [19][20] - Viz's mechanism of action (MOA) as a pupil-selective miotic allows for significant near vision improvement without the side effects associated with previous treatments like pilocarpine [16][18][32] Comparison with Competitors - Vuity, a previous presbyopia eyedrop, had a 25% efficacy rate and only lasted 2-2.5 hours, leading to consumer disappointment [24][25][26] - LENZ Therapeutics claims that Viz is at least three times more effective than Vuity, with a longer duration of action and a broader target population [26][30] Safety and Tolerability - Viz is designed to minimize stimulation of the ciliary muscle, reducing the risk of serious side effects such as retinal detachments [32][33] - The product has shown a low dropout rate of less than 4% in clinical studies, indicating a favorable safety profile [34] International Strategy - LENZ Therapeutics is pursuing licensing agreements for Viz in international markets, including Greater China, Korea, and Southeast Asia, while also submitting an NDA in Europe [35][36] Future Metrics and Expectations - Initial launch metrics will focus on the number of doctors prescribing Viz and the frequency of prescriptions, with plans to share data regularly with investors [14][15][38] Additional Important Content - The company emphasizes the importance of product sampling in driving early adoption and confidence among prescribers [29] - The competitive landscape includes other miotic products, but LENZ believes Viz will dominate due to its unique attributes and consumer demand for effective, long-lasting solutions [30][31]